

Product Information

Anti-GABA_A Receptor (α 3 subunit)

produced in rabbit, affinity isolated antibody

Catalog Number **G4291**

Product Description

Anti-GABA_A Receptor (α 3 subunit (γ -Aminobutyric acid receptor type A α 3 subunit, GABRA3) is produced in rabbit using as immunogen a highly purified peptide QGESR RQEPG DFVKQ (C), corresponding to amino acid residues 1-15 of human GABA_A receptor α 3 subunit (residues 29-43 of the precursor) with an additional C-terminal cysteine. The epitope is specific for the GABA_A α 3 subunit and shares no homology with any other known protein. The epitope is identical in the mouse and rat antigens and highly conserved in the bovine antigen, 14/15 residues identical. The antibody was affinity isolated on immobilized immunogen.

Anti-GABA_A Receptor (α 3 subunit) specifically recognizes the GABA_A receptor α 3 subunit protein and may be used for the detection of the GABA_A receptor α 3 subunit protein (58-60 kDa) in rat brain membrane extracts by immunoblotting and in rat brain frozen sections by immunohistochemistry.

The inhibitory neurotransmitter GABA signals through two distinct types of pre- and postsynaptic receptors, GABA_A and GABA_B. Both GABA receptors can mediate depression of synaptic transmission and contribute to the inhibition controlling neuronal excitability.¹ GABA_A and GABA_B receptors differ with regard to their ionic characteristics and pharmacological properties. The GABA_A receptor is an ionotropic receptor that forms the GABA gated chloride channel and consists of several heterogeneous subunits with membrane recognition sites for benzodiazapenes.² Over the past decade, a family of GABA_A receptor subtypes has been delineated. These subtypes are generated by the co-assembly of five polypeptides selected from the α 1- α 6, β 1- β 3, γ 1- γ 3, δ , ϵ , π and θ subunits.³ The gene transcripts and the polypeptides have distinct patterns of spatial expression such that the GABA_A receptor subtypes have defined locations that are presumed to reflect their physiological function. For example, serotonergic and GABAergic neurons selectively express distinct patterns of α subunits, suggesting they possess distinct GABA_A receptor subtypes.⁴

Serotonergic neurons express strong α 3 immunoreactivity but show no α 1 immunoreactivity. In contrast, GABAergic neurons express both α 1 and α 3 subunits.

GABA_A receptor subtypes also vary with respect to developmental expression patterns.⁵ Developmental changes in the GABA_A receptor subunit composition and the resulting pharmacology will be important in understanding the type of GABA-mediated transmission that takes place between neuronal contacts in the neonatal and, ultimately, the mature brain.

Reagent

Supplied lyophilized at a concentration of 0.3 mg/ml in phosphate buffered saline, pH 7.4, with 1% bovine serum albumin, 5% sucrose and 0.025% sodium azide.

Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.

Preparation Instructions

Reconstitute the lyophilized vial with 0.05 ml or 0.2 ml deionized water, depending on the package size purchased. Antibody dilutions should be made in buffer containing 1-3% bovine serum albumin.

Storage/Stability

Lyophilized powder can be stored intact at room temperature for several weeks. For extended storage, it should be stored at -20 °C or below. Once reconstituted, freeze in working aliquots. Repeated freezing and thawing, or storage in "frost-free" freezers, is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilution samples should be discarded if not used within 12 hours.

Product Profile

Immunoblotting: a recommended working antibody dilution of 1:200 is determined using rat brain membranes.

Immunohistochemistry: a recommended working antibody dilution of 1:200 is determined using rat brain frozen sections.

A procedure for immunohistochemistry has been described for an antibody against the identical epitope.⁴

Note: In order to obtain best results and assay sensitivities of different techniques and preparations, we recommend determining optimal working dilutions by titration test.

References

1. Kerr, D.I. and Ong, J., *Pharmacol. Ther.*, **67**, 187-246 (1995).
2. Kostowski, W., *Pol. J. Pharmacol.*, **47**, 237-246 (1995).
3. Whiting, P.J. et al., *Ann. N.Y. Acad. Sci.*, **868**, 645-653 (1999).
4. Gao, B. et al., *Neuroscience*, **54**, 881-892 (1993).
5. Carlson, B.X. et al., *Eur. J. Pharmacol.*, **352**, 1-14 (1998).

KAA,PHC 07/10-1